DNA-hypomethylating agents are a viable treatment option for AML/myelodysplastic syndrome (MDS) relapse after allograft by upregulating Ags on blasts before DLI. Seventy-two patients with relapsed AML (n = 62), MDS (n = 8) and other myeloid neoplasms (n = 2) after allograft were treated with low-dose 5-azacytidine and, if feasible, DLI. Patient characteristics: median age 62 years (range 20-75), 42% with adverse cytogenetics, 82% not in remission at transplant and 83% received fludarabine-based reducedtoxicity conditioning. Median duration from transplant to 5-azacytidine was 289 days (range 59-2133). Response criteria: CR, temporary disease control or treatment failure. A median of 2.7 courses (range 1-10) were administered; 65 out of 72 patients also received DLI (41 already before 5-azacytidine). Ten patients developed acute GVHD and two succumbed to treatment-related sepsis. CR rate was 9.7% (in two patients lasting 45 years), 44% had temporary disease control (median duration 71 days, range 31-380). Median survival from 5-azacytidine was 108 days, 21 patients proceeded to subsequent transplant. In multivariate analysis, peripheral blood blasts o 1% were predictive of longer OS (P = 0.03). Taken together, long-term remissions can be induced by this well-tolerated outpatient treatment, particularly in patients without peripheral blood blasts.
INTRODUCTION
Azanucleoside treatment of AML and myelodysplastic syndrome (MDS) has finally been accepted as a well-tolerated and effective alternative to low-dose cytarabine (LD-AraC). [1] [2] [3] Given their potent DNA-hypomethylating activities in vitro and in vivo, decitabine and 5-azacytidine are under study regarding their ability to upregulate genes repressed in leukemia, MDS and solid tumors. A very interesting line of research is thus directed to their preclinical and clinical features in the setting of immunomodulation. Thus it is not surprising that rather extensive clinical experience exists with hypomethylating agents (HMAs) in the transplant setting. Others [4] [5] [6] [7] as well as ourselves 8 have demonstrated a good tolerability and very encouraging activity of 5-azacytidine as treatment of AML/ MDS patients who relapsed after allograft. Intriguingly, even a lowdose, 3-day regimen of 5-azacytidine could result in durable CRs in some patients when combined with DLI. 8 After establishing 3-day 5-azacytidine followed by DLI as a routine treatment of relapse after allograft for these myeloid malignancies based on the encouraging experience of the first 26 patients, 8 we can now, in this retrospective analysis, report on the long-term follow-up of these patients as well as on 46 subsequent, consecutive patients receiving this treatment.
PATIENTS AND METHODS Patients
Between October 2006 and August 2013, 72 patients with hematological relapse of AML or MDS after allograft were treated with 5-azacytidine and, if feasible, with DLI. The first 26 patients were previously reported. 8 Inclusion criteria for this program was hematologically relapsed AML or MDS after allograft, no prohibitive GVHD and no option of imminent allograft. Postgraft immunosuppression was discontinued before the relapse treatment. All patients provided informed written consent. Patients were not included if they responded to DLI, had an option of immediate next allograft, a leukemic relapse necessitating immediate institution of chemotherapy, a low performance status and/or uncontrolled infection. Treatment consent and treatment initiation were done centrally within the outpatient clinic of the Section for Hematopoietic Stem Cell Transplantation (Director Professor Jürgen Finke) of the University of Freiburg Medical Center, Freiburg, Germany.
Treatment
Patients were treated with a schedule of 100 mg 5-azacytidine (s.c.) total dose per day on three consecutive days, followed by DLI on day 10, the duration of one course being 21 days, which is until treatment-induced cytopenia had reversed. A 5-day schedule of 100 mg/m 2 5-azacytidine daily as the starting dose (repeated every 3 weeks) was introduced in 2009 for patients with higher leukemic load (leukocytes 410 000/μL and/or peripheral blood blasts ⩾ 1%). A second course was started on day 22 if peripheral blood chimerism was stable after the first course of treatment, without increasing leukocytosis or excessive toxicity, and repeated again 3 weeks later and so on. Treatment cycles were continued until attainment of CR, treatment failure or second hematopoietic SCT. Dose escalations to 125, 150 or 200 mg per day and/or a 4-or 5-day schedule to improve responses were performed in a limited number of patients. Seven patients were switched from a 2-or 3-day schedule to a 4-or 5-day schedule and 3, 13 and 1 patients were escalated from a dose of 100 mg daily to 125, 150 and 200 mg of azacytidine, respectively.
Episodes of infections and other complications necessitating readmission to the hospital during treatment were registered. Neutropenia was scored according to the common toxicity criteria (CTC, v 4.0).
Response criteria and evaluation
Hematologic relapse after transplantation (the inclusion criteria for this program) was defined as 45% blasts in the BM and detection of mixed chimerism. Mixed chimerism was defined as the presence of 45% hostderived cells on more than one occasion in any of the whole blood or the BM samples. Responses to 5-azacytidine were evaluated by BM studies scheduled 6 weeks after the first administration, BM studies were performed earlier in the case of suspected disease progression. A CR was defined as o5% blasts in a BM of adequate cellularity and no Auer rods, absence of leukemic blasts in the peripheral blood, an ANC of ⩾ 1000/μL, platelets of ⩾ 100 000/μL and transfusion independence. 9 Patients not fulfilling CR criteria were scored as having achieved temporary disease control when the mixed chimerism in the peripheral blood remained stable, without evidence of increasing leukocytosis, for at least 4 weeks (chimerism was routinely monitored every 1-2 weeks in the peripheral blood). Patients were scored as treatment failure when no temporary disease control was achieved.
Chimerism and Flt-3 and NPM1 mutational status analyses Quantification of chimerism was carried out on marrow and/or peripheral blood samples by FISH or by a variable number of tandem repeat studies as described earlier. 10 Flt-3 and NPM1 mutational status was determined using BM and/or peripheral blood blast cells as described. 11, 12 Statistical methods Median survival was calculated from the first day of 5-azacytidine treatment to death or last follow-up using the Kaplan-Meier method. Patients who received a subsequent transplant were not censored. Differences in response rate and OS were studied on the following pretreatment variables: age ( o60 vs ⩾ 60 years), donor age (⩽40 vs 440 years), leukocyte count (o 5000 vs ⩾ 5000/μL), peripheral blood blasts (o1 vs ⩾ 1%), BM blasts (o 20 vs ⩾ 20%), European LeukemiaNet cytogenetic risk (favorable or intermediate vs adverse), time from transplant to relapse (o 36 weeks vs ⩾ 36 weeks), DLI before the first course of 5-azacytidine, unrelated blood stem cell donor and male patient with female donor. Differences in response rate by these subgroups were analyzed univariate for substantial correlation applying ϕ-Statistics, Cramer's V 2-sided, exact was calculated. The adjustment using Abbreviations: CBF = core binding factor; CK = complex karyotype; CMML = chronic myelomonocytic leukemia; ELN = European Leukemia Net; ET = essential thrombocythemia; IPSS = International Prognostic Scoring System; MDS = myelodysplastic syndrome; MK = monosomal karyotype; NHL = non-Hodgkin's lymphoma; OMF = osteomyelofibrosis; PCV = polycythemia vera; RAEB = refractory anemia with excess blasts; RCMD = refractory cytopenia with multilineage dysplasia. multivariate analyses with ordinal regression was not possible owing to limited data availability. Differences in OS were studied by univariate analyses applying log-rank tests. A significance level of 5% was chosen. All the variables with P ⩽ 0.1 were included in a Cox-regression multivariate analysis. A P-value of ⩽ 0.05 was considered to be statistically significant for all the statistical tests.
RESULTS

Patient characteristics and treatment
Between October 2006 and August 2013, 72 patients with a median age of 62 years (range 20-75, 46 male and 26 female) who had a hematologic relapse or had mixed chimerism (two patients) after allograft were included to receive 5-azacytidine treatment. Diagnoses were AML (n = 62), MDS (n = 6), chronic myelomonocytic leukemia (n = 2), acute mast cell leukemia and blastic plasmacytoid dendritic cell neoplasm (n = 1 each). Out of 67 patients with obtained karyotype, 23 patients had a normal karyotype and 44 patients had cytogenetic abnormalities, with 6 patients having a monosomal karyotype as defined by Breems et al. 13 Forty-six of 58 with information on NPM1 and Flt3 mutational status (64%) had intermediate-2 or adverse cytogenetics according to European LeukemiaNet or International Prognostic Scoring System criteria. Detailed patient characteristics are given in Tables 1 and 2 .
Forty-seven patients (65%) and 18 patients (25%) received a 3-and 5-day course of 5-azacytidine, respectively, as a starting dose. In three (4%) and four patients (6%), the initial dosing was for 2 and 4 days, respectively. Dose escalation were initiated as indicated above to improve the responses. 5-Azacytidine was followed by DLI on day 10 where feasible, and the next treatment course was scheduled to start at day 22, that is, within a 3-week cycle. The subsequent courses also contained at least one DLI if feasible and available to enhance the effect of this combination. Administered DLI doses varied between 0.3 and 2×10 6 cells/kg bodyweight at treatment start.
Treatment before start of and with 5-azacytidine varied ( Figure 1 ): 41 out of 72 patients received DLI already before the 5-azacytidine treatment (time between transplant and start of azacytidine, median 289 days, range 59-2133 days) and in combination, given prophylactically (four patients), because of: mixed chimerism but no overt hematological relapse (24 patients), isolated intrathecal relapse, also given prophylactically (one patient), or hematological relapse (12 patients). Twenty-four patients received DLI only in combination with 5-azacytidine. Nine patients received DLI only before the 5-azacytidine treatment, but not in combination, and seven patients did not receive DLI at all, either because of GVHD or because they had no DLI available.
Toxicities
Out of the 72 patients, 28 had to be readmitted at least once to the hospital because of infectious complications, necessitating a total of 36 hospitalizations. Fifteen were associated with grade III/IV neutropenia and 14 with progression of disease. In two patients, the neutropenia-associated complications were fatal (urosepsis with Enterobacter cloacae and pneumogenic sepsis, respectively). Other non-severe gastrointestinal symptoms (obstipation, diarrhea and nausea) and skin irritation after 5-azacytidine injections were observed in a limited number of patients.
GVHD
Nine of the 72 patients showed signs of chronic GVHD (cGVHD) already before the start of treatment with 5-azacytidine: five patients showed cGVHD grade I-II, three patients cGVHD grade III and one patient cGVHD grade IV, who therefore did not receive DLI. One of the patients with grade III GVHD did not receive DLI, the other two had stable or regressive disease before the treatment and did not experience aggravation of GVHD under 5-azacytidine/DLI treatment.
Ten patients developed acute or chronic GVHD during the treatment with 5-azacytidine/DLI (Figure 1 ): six patients developed grade I-II cutaneous acute GVHD, one patient developed grade IV cutaneous cGVHD after five courses of DLI, which regressed after the treatment stopped. One patient, who had no signs of GVHD before the treatment, developed cGVHD of the skin 3 weeks after the last DLI (patient received seven courses of DLI, five in combination with 5-azacytidine), simultaneously achieving a CR with complete chimerism (CC). At the time of this report the patient is still in CR with CC, with extensive cGVHD of the skin and eyes. One patient developed grade II hepatic and grade I cutaneous cGVHD while in CR, 2 months after the last 5-azacytidine/DLI course, and one additional patient developed localized acute GVHD of the colon ascendens (grade IV) during treatment.
Response rate and survival Thirty-nine of the 72 patients (54%) fulfilled the response criteria for the treatment, with CR noted in seven patients (9.7%; Table 3 ), in two of them now lasting more than 6 years. Six of the patients converted to CC (duration 68+, 67+, 36+, 20+, 15+ and 2+ months.). One responder (duration 38+ months) represented a 'split chimerism' with persistence of mixed chimerism despite blast clearance in the BM and normalization of peripheral blood counts. One patient had only mixed chimerism but no hematological relapse at the start of treatment and regained CC and a CR lasting for 15 months. Thirty-two patients (44%) had temporary disease control with stable mixed chimerism (median duration 71 days, range 31-380 days) and stable leukocyte count, with two patients converting to complete donor chimerism lasting for 146 and 380 days, respectively. In the remaining 33 patients, no disease control was achieved. No statistically significant difference in OS could be seen between the groups receiving a 2-or 3-day schedule and a 4-or 5-day schedule (median OS 27.4 vs 13.2 weeks, P = 0.37).
We analyzed 10 predictive factors for OS in a univariate analysis (Supplementary Table 2 ), five were significant at P ⩽ 0.1 and thus subjected to a multivariate analysis (Cox model; Table 4 ). In this multivariate analysis, peripheral blood blasts o 1% retained their predictive value for longer OS (32.7 vs 14.7 weeks, P = 0.03, hazard Abbreviations: CI = confidence of interval; HR = hazard ratio. Figure 2 . OS (in weeks) for all 72 patients from first day of 5-azacytidine to death or last follow-up, including 21 patients (29%) with a second transplant (+ censored patients (alive)).
ratio 1 vs 1.98, confidence interval (1.07, 3.66) ). The same 10 predictive factors were analyzed for best response in a univariate analysis (Supplementary Table 1 ). Time ⩾ 36 weeks from transplant to relapse (P = 0.019) and DLI before 5-azacytidine (P = 0.06) showed predictive value for best response. Multivariate analysis could not be performed due to limited data availability. Of the 72 patients, 9 are alive at time of the last follow-up. Twenty-two patients proceeded to subsequent transplant after 5-azacytidine and/or DLI treatment, four of them (19%) are alive at the time of this report. The median survival from start of 5-azacytidine was 108 days, as shown in Figure 2 .
DISCUSSION
Relapse of AML or MDS after allograft until recently heralded a dismal prognosis regarding long-term outcome, with only a few salvage treatments and no international standards. We and others have initiated programs of azanucleoside treatment in the setting of either bridging to second transplant or as an-albeit usually noncurative-option to control the disease with a well-tolerated, easily administered outpatient regimen. 6, 7, [14] [15] [16] In an extension of a previous encouraging experience of 26 patients, 8 we now report a total of 72 patients, mostly with AML, many of them older than 60 years and with adverse cytogenetics. It was gratifying to note that we could confirm the initial overall response rate of 450%, with achievement of very durable, unmaintained CRs in about half the patients attaining CR.
With this extended cohort it was now possible to perform multivariate analyses to identify factors associated with better survival after initiation of 5-azacytidine/DLI. These confirm the preliminary result (based on only univariate analysis due to the limited number of patients). Although the multivariate model has its limitations owing to rather great variation in dosing and patient characteristics, it indicates that the absence of peripheral blood blasts at time of treatment start predicted better outcome.
DLI administration before 5-azacytidine also tended to predict better outcome, as did longer duration of remission after initial transplant; however, the group receiving DLI before aza had somewhat lower relapse parameters than patients with no DLI treatment before 5-azacytidine: peripheral blood blasts, median 0 vs 4.5%; BM blasts, median 20% vs 45%; and WBC, median 3 vs 4.9 Tsd/μL. These differences were not statistically significant. (As there was heterogeneity in treatment schedules and doses in this retrospectively analyzed cohort, conclusions have to be drawn carefully.) Twenty-two of the 72 patients (30%) received a subsequent allograft after this bridging strategy, with a survival advantage of 340 days from the start of 5-azacytidine to death or last follow-up compared with 94 days without a second transplant. Four of these patients are alive at the time of this analysis. In line with our previous report, 8 of the remaining 50 patients (70%) 4 are alive and in remission. Interestingly, they all had received previous DLI. One patient was alive with progressive disease at time of analysis.
Further studies should be directed at better identifying the features predictive for this excellent response that may be tantamount to cure in some patients. It is notable that the rate of GVHD was confirmed to be rather low also in this extended cohort, which also may be an indicator for the immunomodulatory potency of azanucleosides, as carefully shown by several groups. 17, 18 Schroeder et al. 19 recently showed in a prospective trial that 5-azacytidine is capable of increasing regulatory T cells, especially in patients relapsing early after allo-SCT, and thus preventing development of GVHD following the DLI treatment.
A substantial number of patients had already received DLI alone before the 5-azacytidine/DLI combination, but without achieving CC, justifying the treatment on this program. Notably, in these patients the 5-azacytidine/DLI treatment was often active, whereas DLI alone had not been, suggesting that 5-azacytidine was able to reinforce the DLI effect. Possibly, 5-azacytidine acted as a 'priming' agent and sensitizer to the immune cells, for instance by upregulating cancer/testis antigens in vivo. 20, 21 This robust clinical result (very notable particularly in the patients attaining prolonged complete remission, all of whom had received previous DLI only, without attaining CR) add to the clinical settings where azanucleoside treatment can prime leukemia cells or solid tumors to the activity of the subsequent therapy.
New data on the effect of HMAs on the expression of the coinhibitory molecules PD-1, PD-L1, PD-L2 and CTLA4 and the possibility of their involvement in resistance mechanisms to HMAs is important and very interesting regarding potential combination strategies of HMAs with PD-1 and PD-L1 inhibitors. 22 Given the overall disappointing outcome of patients presenting with more aggressive relapse in the initial cohort of 26 patients, we had in 2009 markedly increased the initial 5-azacytidine dosing on the basis of several features of disease dynamics, including excess peripheral blood blasts. Nonetheless, of the 18 patients now analyzed who had received 100 mg/m 2 on 5 days, only 1 patient achieved a CR and the rate of temporary disease control was only 18% (3 patients), thus still far below the outcome in patients without these features, who had received the 3-day treatment.
The CR rate of 9.7% in this analysis was lower than that in other studies with this approach, for example, Tessoulin et al. 23 (CR 14%, overall response rate (ORR) 29%), Schroeder et al. 6 (CR 23%, ORR 30%) and Czibere et al. 5 (CR 23%, ORR 72%). One possible reason for this is the lower dosage (2, 3 or 4 days) of 5-azacytidine 100 mg per day, which 75% of our patients received as a starting dose. Importantly, patients in our cohort were older, with a median of 62 years compared with 57, 55 and 50 years, respectively, in the above-mentioned studies, which likely contributed to the lower response rate.
Very recently, encouraging results were published of eight pediatric and young adult AML patients relapsed after allograft who received the 10-day decitabine schedule that is actively developed as frontline treatment of AML. 15 To further explore this DNA-HMA, it would be interesting to investigate the effect of decitabine, followed by DLI, in comparison with 5-azacytidine. In that regard, in a comparative in vitro study, decitabine was more effective than 5-azacytidine in upregulating cancer/testis antigens on AML cells. 24 In conclusion, based on this large series of AML/MDS patients treated with 5-azacytidine/DLI, this approach proves to be an effective, well-tolerated bridge to second transplant, and results in at least temporary disease control in the majority of patients with a relapse after allografting. However, the still limited CR rate may be enhanced by increasing the total dose of the azanucleoside per course. Also the results with patients presenting with aggressive relapse are not yet satisfactory. Here, possible treatment modifications include drug exposure beyond 5 days, use of more powerful DNA-HMAs and possibly a higher initial DLI dosing. Translational studies on primary blasts before and after hypomethylating treatment are warranted to address whether derepression of genes silenced by hypermethylation is causal in boosting immune responses in vivo. 21, 25 
